[Click eStock] "Kangstem Biotech, Anticipation Grows for Clinical Data Presentation at Next Month's World Osteoarthritis Congress"

Independent research firm ValueFinder analyzed on the 5th that Gangstem Biotech is expected to raise anticipation as it plans to present clinical data on its osteoarthritis treatment (OSCA) at the upcoming World Congress on Osteoarthritis next month.

Researcher Lee Chungheon of ValueFinder stated in the report, “OSCA is a next-generation disease-modifying osteoarthritis drug (DMOAD) candidate developed by the company, with its main components being allogeneic umbilical cord blood-derived mesenchymal stem cells and acellular cartilage ECM (CAM). While existing osteoarthritis treatments mainly focus on symptom relief, OSCA has the potential to simultaneously induce cartilage regeneration and improve joint structure, thereby slowing or even reversing disease progression. Notably, unlike other companies’ knee perforation methods involving incisions, OSCA can be administered via injection without surgery or incisions, offering significant advantages in treatment convenience and reducing patient burden.”

He added, “Osteoarthritis accounts for 11% of the global disease burden, with approximately 600 million patients worldwide suffering from it. Among them, the target patient population for OSCA, those with knee osteoarthritis, is estimated at 400 million (two-thirds of the total). The number of osteoarthritis patients is 32 times greater than that of rheumatoid arthritis patients, yet the market size for osteoarthritis treatments is only about one-fifth that of rheumatoid arthritis. Therefore, if OSCA is launched as a fundamental treatment (DMOAD) in the osteoarthritis market, it is expected to become a global blockbuster drug.”

Furthermore, the researcher noted, “The company has already confirmed anti-inflammatory and cartilage regeneration effects through OSCA’s Phase 1 clinical trial and signed a domestic license-out (L/O) agreement with Yu Young Pharmaceutical, a Korean musculoskeletal specialist pharmaceutical company, in November last year. In March of this year, dosing for a Phase 2a clinical trial targeting patients with moderate osteoarthritis is scheduled to begin, and in April, the company plans to present Phase 1 MRI results at the World Congress on Osteoarthritis (OARSI). This is expected to enhance OSCA’s clinical credibility and elicit positive evaluations from global big pharma. According to media reports, CEO Kang Kyung-sun visited the JP Morgan Healthcare Conference in January this year and received inquiries about technology export from numerous global companies.”